BDRX VS NVIV Stock Comparison
Performance
BDRX10/100
10/100
BDRX returned -98.01% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
NVIV10/100
10/100
NVIV returned -73.96% in the last 12 months. Based on SPY's performance of -13.87%, its performance is below average giving it a score of 10 of 100.
Volatility
BDRX71/100
71/100
BDRX has had a higher than average amount of volatility over the last 12 months giving it a score of 71 of 100.
NVIV40/100
40/100
NVIV has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
Analyst Price Targets
BDRX
"Analyst Price Targets" not found for BDRX
NVIV75/100
75/100
2 analysts offer 12-month price targets for NVIV. Together, they have an average target of 0, the most optimistic target put NVIV at 0 within 12-months and the most pessimistic has NVIV at 0.
Technicals
BDRX
"Technicals" not found for BDRX
NVIV14/100
14/100
NVIV receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
BDRX
"Earnings" not found for BDRX
NVIV10/100
10/100
NVIV has missed earnings 5 times in the last 20 quarters.
Profit
BDRX
"Profit" not found for BDRX
NVIV10/100
10/100
Out of the last 20 quarters, NVIV has had 0 profitable quarters and has increased their profits year over year on 0 of them.
All score calculations are broken down here to help you make more informed investing decisions
Biodexa Pharmaceuticals plc American Depositary Shs Summary
Nasdaq / BDRX
Healthcare
Biotechnology
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
InVivo Therapeutics Holdings Corp Summary
Nasdaq / NVIV
Healthcare
Biotechnology
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare BDRX to other companies in the same or a similar industry.